Covance & BioPontis Alliance Collaborate to Bridge Drug Development Gap
PRINCETON, N.J. - Covance Inc. (NYSE: CVD) has announced the signing of a three-year, exclusive integrated drug development agreement with BioPontis Alliance to manage early development of scientific discoveries from academia. The agreement provides that Covance will be the exclusive provider to BioPontis Alliance of drug development services, including discovery support, preclinical, bioanalytical, CMC, clinical, central labs and commercialization.
Sourcing discovery science through collaborative relationships with leading research universities and other institutions, BioPontis Alliance identifies and develops early stage discoveries and technologies, providing the medical industry with efficient access to preclinical innovation. In this unique early development model, Covance will integrate and manage the services required to move a compound from lead optimization into the clinic, providing the scientific and operational continuity that reduces the feasibility gap between academic intellectual property and human proof of concept.
Click here for full article.
There's a glimmer of hope seen in a new optimism among employers